Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

High-Throughput Fluorescence Assays for Ion Channels and GPCRs.

Vetter I, Carter D, Bassett J, Deuis JR, Tay B, Jami S, Robinson SD.

Adv Exp Med Biol. 2020;1131:27-72. doi: 10.1007/978-3-030-12457-1_3. Review.

PMID:
31646506
2.

Antiallodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute postsurgical pain: evidence for analgesic synergy with opioids and baclofen.

Mueller A, Starobova H, Morgan M, Dekan Z, Cheneval O, Schroeder CI, Alewood PF, Deuis JR, Vetter I.

Pain. 2019 Aug;160(8):1766-1780. doi: 10.1097/j.pain.0000000000001567.

PMID:
31335646
3.

Inflammatory and Neuropathic Gene Expression Signatures of Chemotherapy-Induced Neuropathy Induced by Vincristine, Cisplatin, and Oxaliplatin in C57BL/6J Mice.

Starobova H, Mueller A, Deuis JR, Carter DA, Vetter I.

J Pain. 2019 Jun 29. pii: S1526-5900(19)30751-5. doi: 10.1016/j.jpain.2019.06.008. [Epub ahead of print]

PMID:
31260808
4.

NaV 1.6 regulates excitability of mechanosensitive sensory neurons.

Israel MR, Tanaka BS, Castro J, Thongyoo P, Robinson SD, Zhao P, Deuis JR, Craik DJ, Durek T, Brierley SM, Waxman SG, Dib-Hajj SD, Vetter I.

J Physiol. 2019 Jul;597(14):3751-3768. doi: 10.1113/JP278148. Epub 2019 May 13.

PMID:
31087362
5.

Anti-allodynic effects of the selective NaV1.7 inhibitor Pn3a in a mouse model of acute post-surgical pain: evidence for analgesic synergy with opioids and baclofen.

Mueller A, Starobova H, Morgan M, Dekan Z, Cheneval O, Schroeder CI, Alewood PF, Deuis JR, Vetter I.

Pain. 2019 Mar 21. doi: 10.1097/j.pain.0000000000001567. [Epub ahead of print]

PMID:
30908355
6.

Development of a high-throughput fluorescent no-wash sodium influx assay.

Tay B, Stewart TA, Davis FM, Deuis JR, Vetter I.

PLoS One. 2019 Mar 11;14(3):e0213751. doi: 10.1371/journal.pone.0213751. eCollection 2019.

7.

A Centipede Toxin Family Defines an Ancient Class of CSαβ Defensins.

Dash TS, Shafee T, Harvey PJ, Zhang C, Peigneur S, Deuis JR, Vetter I, Tytgat J, Anderson MA, Craik DJ, Durek T, Undheim EAB.

Structure. 2019 Feb 5;27(2):315-326.e7. doi: 10.1016/j.str.2018.10.022. Epub 2018 Dec 13.

PMID:
30554841
8.

Toxins as tools: Fingerprinting neuronal pharmacology.

Israel MR, Morgan M, Tay B, Deuis JR.

Neurosci Lett. 2018 Jul 13;679:4-14. doi: 10.1016/j.neulet.2018.02.001. Epub 2018 Feb 6. Review.

PMID:
29425731
9.

The E15R Point Mutation in Scorpion Toxin Cn2 Uncouples Its Depressant and Excitatory Activities on Human NaV1.6.

Israel MR, Thongyoo P, Deuis JR, Craik DJ, Vetter I, Durek T.

J Med Chem. 2018 Feb 22;61(4):1730-1736. doi: 10.1021/acs.jmedchem.7b01609. Epub 2018 Feb 3.

PMID:
29378414
10.

Role of complement anaphylatoxin receptors in a mouse model of acute burn-induced pain.

Morgan M, Deuis JR, Woodruff TM, Lewis RJ, Vetter I.

Mol Immunol. 2018 Feb;94:68-74. doi: 10.1016/j.molimm.2017.12.016. Epub 2017 Dec 21.

PMID:
29274925
11.

Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species.

Muttenthaler M, Andersson Å, Vetter I, Menon R, Busnelli M, Ragnarsson L, Bergmayr C, Arrowsmith S, Deuis JR, Chiu HS, Palpant NJ, O'Brien M, Smith TJ, Wray S, Neumann ID, Gruber CW, Lewis RJ, Alewood PF.

Sci Signal. 2017 Dec 5;10(508). pii: eaan3398. doi: 10.1126/scisignal.aan3398.

12.

Burn Pain: A Systematic and Critical Review of Epidemiology, Pathophysiology, and Treatment.

Morgan M, Deuis JR, Frøsig-Jørgensen M, Lewis RJ, Cabot PJ, Gray PD, Vetter I.

Pain Med. 2018 Apr 1;19(4):708-734. doi: 10.1093/pm/pnx228.

PMID:
29036469
13.

Methods Used to Evaluate Pain Behaviors in Rodents.

Deuis JR, Dvorakova LS, Vetter I.

Front Mol Neurosci. 2017 Sep 6;10:284. doi: 10.3389/fnmol.2017.00284. eCollection 2017.

14.

Discovery and mode of action of a novel analgesic β-toxin from the African spider Ceratogyrus darlingi.

Sousa SR, Wingerd JS, Brust A, Bladen C, Ragnarsson L, Herzig V, Deuis JR, Dutertre S, Vetter I, Zamponi GW, King GF, Alewood PF, Lewis RJ.

PLoS One. 2017 Sep 7;12(9):e0182848. doi: 10.1371/journal.pone.0182848. eCollection 2017.

15.

Corrigendum: Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a.

Deuis JR, Dekan Z, Wingerd JS, Smith JJ, Munasinghe NR, Bhola RF, Imlach WL, Herzig V, Armstrong DA, Rosengren KJ, Bosmans F, Waxman SG, Dib-Hajj SD, Escoubas P, Minett MS, Christie MJ, King GF, Alewood PF, Lewis RJ, Wood JN, Vetter I.

Sci Rep. 2017 May 26;7:46816. doi: 10.1038/srep46816. No abstract available.

16.

Modulatory features of the novel spider toxin μ-TRTX-Df1a isolated from the venom of the spider Davus fasciatus.

Cardoso FC, Dekan Z, Smith JJ, Deuis JR, Vetter I, Herzig V, Alewood PF, King GF, Lewis RJ.

Br J Pharmacol. 2017 Aug;174(15):2528-2544. doi: 10.1111/bph.13865. Epub 2017 Jun 27.

17.

Sodium Channels and Venom Peptide Pharmacology.

Israel MR, Tay B, Deuis JR, Vetter I.

Adv Pharmacol. 2017;79:67-116. doi: 10.1016/bs.apha.2017.01.004. Epub 2017 Apr 8. Review.

PMID:
28528674
18.

Δ-Myrtoxin-Mp1a is a Helical Heterodimer from the Venom of the Jack Jumper Ant that has Antimicrobial, Membrane-Disrupting, and Nociceptive Activities.

Dekan Z, Headey SJ, Scanlon M, Baldo BA, Lee TH, Aguilar MI, Deuis JR, Vetter I, Elliott AG, Amado M, Cooper MA, Alewood D, Alewood PF.

Angew Chem Int Ed Engl. 2017 Jul 10;56(29):8495-8499. doi: 10.1002/anie.201703360. Epub 2017 Jun 13.

PMID:
28513074
19.

The pharmacology of voltage-gated sodium channel activators.

Deuis JR, Mueller A, Israel MR, Vetter I.

Neuropharmacology. 2017 Dec;127:87-108. doi: 10.1016/j.neuropharm.2017.04.014. Epub 2017 Apr 14. Review.

PMID:
28416444
20.

The structure, dynamics and selectivity profile of a NaV1.7 potency-optimised huwentoxin-IV variant.

Rahnama S, Deuis JR, Cardoso FC, Ramanujam V, Lewis RJ, Rash LD, King GF, Vetter I, Mobli M.

PLoS One. 2017 Mar 16;12(3):e0173551. doi: 10.1371/journal.pone.0173551. eCollection 2017.

21.

Multiple sodium channel isoforms mediate the pathological effects of Pacific ciguatoxin-1.

Inserra MC, Israel MR, Caldwell A, Castro J, Deuis JR, Harrington AM, Keramidas A, Garcia-Caraballo S, Maddern J, Erickson A, Grundy L, Rychkov GY, Zimmermann K, Lewis RJ, Brierley SM, Vetter I.

Sci Rep. 2017 Feb 22;7:42810. doi: 10.1038/srep42810.

22.

Pharmacological characterisation of the highly NaV1.7 selective spider venom peptide Pn3a.

Deuis JR, Dekan Z, Wingerd JS, Smith JJ, Munasinghe NR, Bhola RF, Imlach WL, Herzig V, Armstrong DA, Rosengren KJ, Bosmans F, Waxman SG, Dib-Hajj SD, Escoubas P, Minett MS, Christie MJ, King GF, Alewood PF, Lewis RJ, Wood JN, Vetter I.

Sci Rep. 2017 Jan 20;7:40883. doi: 10.1038/srep40883. Erratum in: Sci Rep. 2017 May 26;7:46816.

23.

Role of the NLRP3 inflammasome in a model of acute burn-induced pain.

Deuis JR, Yin K, Cooper MA, Schroder K, Vetter I.

Burns. 2017 Mar;43(2):304-309. doi: 10.1016/j.burns.2016.09.001. Epub 2016 Dec 28.

PMID:
28040362
24.

NaV1.7 as a pain target - From gene to pharmacology.

Vetter I, Deuis JR, Mueller A, Israel MR, Starobova H, Zhang A, Rash LD, Mobli M.

Pharmacol Ther. 2017 Apr;172:73-100. doi: 10.1016/j.pharmthera.2016.11.015. Epub 2016 Dec 2. Review. No abstract available.

PMID:
27916648
25.

The thermal probe test: A novel behavioral assay to quantify thermal paw withdrawal thresholds in mice.

Deuis JR, Vetter I.

Temperature (Austin). 2016 Feb 26;3(2):199-207. eCollection 2016 Apr-Jun.

26.

The Snake with the Scorpion's Sting: Novel Three-Finger Toxin Sodium Channel Activators from the Venom of the Long-Glanded Blue Coral Snake (Calliophis bivirgatus).

Yang DC, Deuis JR, Dashevsky D, Dobson J, Jackson TN, Brust A, Xie B, Koludarov I, Debono J, Hendrikx I, Hodgson WC, Josh P, Nouwens A, Baillie GJ, Bruxner TJ, Alewood PF, Lim KK, Frank N, Vetter I, Fry BG.

Toxins (Basel). 2016 Oct 18;8(10). pii: E303.

27.

Transcriptomic and behavioural characterisation of a mouse model of burn pain identify the cholecystokinin 2 receptor as an analgesic target.

Yin K, Deuis JR, Lewis RJ, Vetter I.

Mol Pain. 2016 Aug 28;12. pii: 1744806916665366. doi: 10.1177/1744806916665366. Print 2016.

28.

Development of a μO-Conotoxin Analogue with Improved Lipid Membrane Interactions and Potency for the Analgesic Sodium Channel NaV1.8.

Deuis JR, Dekan Z, Inserra MC, Lee TH, Aguilar MI, Craik DJ, Lewis RJ, Alewood PF, Mobli M, Schroeder CI, Henriques ST, Vetter I.

J Biol Chem. 2016 May 27;291(22):11829-42. doi: 10.1074/jbc.M116.721662. Epub 2016 Mar 29.

29.

Analgesic Effects of GpTx-1, PF-04856264 and CNV1014802 in a Mouse Model of NaV1.7-Mediated Pain.

Deuis JR, Wingerd JS, Winter Z, Durek T, Dekan Z, Sousa SR, Zimmermann K, Hoffmann T, Weidner C, Nassar MA, Alewood PF, Lewis RJ, Vetter I.

Toxins (Basel). 2016 Mar 17;8(3). pii: E78. doi: 10.3390/toxins8030078.

30.

Activation of κ Opioid Receptors in Cutaneous Nerve Endings by Conorphin-1, a Novel Subtype-Selective Conopeptide, Does Not Mediate Peripheral Analgesia.

Deuis JR, Whately E, Brust A, Inserra MC, Asvadi NH, Lewis RJ, Alewood PF, Cabot PJ, Vetter I.

ACS Chem Neurosci. 2015 Oct 21;6(10):1751-8. doi: 10.1021/acschemneuro.5b00113. Epub 2015 Aug 12.

PMID:
26225903
31.

Identification and Characterization of ProTx-III [μ-TRTX-Tp1a], a New Voltage-Gated Sodium Channel Inhibitor from Venom of the Tarantula Thrixopelma pruriens.

Cardoso FC, Dekan Z, Rosengren KJ, Erickson A, Vetter I, Deuis JR, Herzig V, Alewood PF, King GF, Lewis RJ.

Mol Pharmacol. 2015 Aug;88(2):291-303. doi: 10.1124/mol.115.098178. Epub 2015 May 15.

PMID:
25979003
32.

α-Conotoxin MrIC is a biased agonist at α7 nicotinic acetylcholine receptors.

Mueller A, Starobova H, Inserra MC, Jin AH, Deuis JR, Dutertre S, Lewis RJ, Alewood PF, Daly NL, Vetter I.

Biochem Pharmacol. 2015 Mar 15;94(2):155-63. doi: 10.1016/j.bcp.2015.01.011. Epub 2015 Jan 31.

PMID:
25646788
33.

Analgesic effects of clinically used compounds in novel mouse models of polyneuropathy induced by oxaliplatin and cisplatin.

Deuis JR, Lim YL, Rodrigues de Sousa S, Lewis RJ, Alewood PF, Cabot PJ, Vetter I.

Neuro Oncol. 2014 Oct;16(10):1324-32. doi: 10.1093/neuonc/nou048. Epub 2014 Apr 8.

34.

Analgesic treatment of ciguatoxin-induced cold allodynia.

Zimmermann K, Deuis JR, Inserra MC, Collins LS, Namer B, Cabot PJ, Reeh PW, Lewis RJ, Vetter I.

Pain. 2013 Oct;154(10):1999-2006. doi: 10.1016/j.pain.2013.06.015. Epub 2013 Jun 15.

PMID:
23778293
35.

An animal model of oxaliplatin-induced cold allodynia reveals a crucial role for Nav1.6 in peripheral pain pathways.

Deuis JR, Zimmermann K, Romanovsky AA, Possani LD, Cabot PJ, Lewis RJ, Vetter I.

Pain. 2013 Sep;154(9):1749-57. doi: 10.1016/j.pain.2013.05.032. Epub 2013 May 24.

Supplemental Content

Loading ...
Support Center